Latest Imatinib Stories
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/
- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb.
The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient.
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs.
- A person in a secondary role, specifically the second most important character (after the protagonist).